Preservation and Expansion of T-cell Subsets Following HAART De-intensification to Atazanavir/Ritonavir (ATV/r)

NACompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
HIV Infections
Interventions
PROCEDURE

Early Initiation of Highly Active Anti-Retroviral Therapy

Treatment: TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r or other recommended NRTI backbone with ATV/r. Duration: Subjects in the experimental group who achieve virologic control by week 24 and maintain good control through 48 weeks will then de-intensify to ATV/r alone and will be followed for an additional two years.

PROCEDURE

Standard Care

Progression: Subjects on the standard care arm will begin therapy when the CD4+ T cell count drops below 350 cells/mm3 or other clinical criteria necessitating treatment as determined by the site clinician occur. Treatment: HAART with TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r, or other recommended ATV/r based HAART regimen according to current DHHS standard of care. Duration: three years.

Trial Locations (23)

10128

Mount Sinai Medical Center, New York

10467

Montefiore Medical Center, The Bronx

19104

Children's Hospital of Philadelphia, Philadelphia

20010

Children's National Medical Center, Washington D.C.

20060

Howard University - IMPAACT Site, Washington D.C.

21201

University of Maryland, Baltimore

21287

Johns Hopkins University - IMPAACT Site, Baltimore

27710

Duke Pediatric Infectious Diseases - IMPAACT Site, Durham

33101

University of Miami, Miami

33316

Children's Diagnostic and Treatment Center, Fort Lauderdale

33606

University of Southern Florida College of Medicine, Tampa

38105

St. Jude Children's Research Hospital (Memphis) - IMPAACT Site, Memphis

St. Jude Childrens Research Hospital, Memphis

48201

Children's Hospital of Michigan - IMPAACT Site, Detroit

60612

Stoger Hospital of Cook County, Chicago

60614

Childrens Memorial Hospital, Chicago

70112

Tulane Medical Center, New Orleans

80045

Children's Hospital of Denver - IMPAACT Site, Aurora

90027

Children's Hopsital of Los Angeles, Los Angeles

90033

University of Southern California - IMPAACT Site, Los Angeles

94118

University of California at San Francisco, San Francisco

07103

UMDNJ - IMPAACT Site, Newark

00927

University of Puerto Rico, San Juan

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

National Institute of Mental Health (NIMH)

NIH

collaborator

International Maternal Pediatric Adolescent AIDS Clinical Trials Group

NETWORK

lead

University of North Carolina, Chapel Hill

OTHER

NCT00491556 - Preservation and Expansion of T-cell Subsets Following HAART De-intensification to Atazanavir/Ritonavir (ATV/r) | Biotech Hunter | Biotech Hunter